Weekly Digest – August 2024 Weekly Digest – August 2024 05 Aug 2024: Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of JK06, a 5T4-Targeted ADC, in Solid Tumors Salubris Biotherapeutics has received EMA […]
Monthly Digest – August 2024 Monthly Digest – August 2024 31 July 2024: IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen IDEAYA Biosciences and Biocytogen Pharmaceuticals have entered into an option […]
Monthly Digest – August 2024 Monthly Digest – August 2024 31 July 2024: AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 AC Immune introduced morADC, a novel class of […]
Monthly Digest – August 2024 Monthly Digest – August 2024 01 Aug 2024: OS Therapies refiles IPO for a modest $6M to fund phase 2 HER2 drug, preclinical ADCs OS Therapies is listing on the NYSE American with a $6.4 […]
